Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

ALLERGAN, INC. (AGN)

35
SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Allergan, Inc. : Allergan 3rd-Quarter Profit Edges Down; Weighs Options for Obesity Segment

10/30/2012 | 09:07am US/Eastern
   By Tess Stynes 
 

Allergan Inc.'s (AGN) third-quarter earnings edged down slightly as the maker of Botox and medical devices posted more one-time items, masking continued sales growth for top drug Botox.

Since the end of the quarter, Allergan said it is exploring strategic options for its obesity intervention business, including among other things, a potential sale of the unit.

For the year, the company raised the lower end of its guidance and now expects per-share earnings of $4.17 and $4.19 on product sales of $5.7 billion to $5.8 billion. Its prior view was for per-share profit of $4.15 to $4.19 and product sales of $5.65 billion to $5.8 billion.

For the current quarter, Allergan forecast per-share earnings of $1.18 to $1.20 on revenue of $1.47 billion to $1.55 billion. Analysts polled by Thomson Reuters most recently expected $1.20 and $1.51 billion, respectively.

Chief Executive David E.I. Pyott in August had commented that the company is watching carefully for signs of economic vulnerability, but doesn't see a threat to long-term goals. Allergan's cosmetic medical products seem to appeal to people with greater economic means and purchasing power, providing some shelter from economic turmoil, he said at the time.

Allergan reported a profit of $249.4 million, down from $249.8 million a year earlier. On a per-share basis, earnings were up at 82 cents from 81 cents amid fewer shares outstanding. Excluding acquisition and restructuring related charges and other items, earnings were up at $1.06 from 92 cents.

Revenue increased 6.4% to $1.41 billion. Product net sales were up 6.1% to $1.39 billion, and were up 9.4% excluding currency impacts.

The company in August forecast per-share earnings of $1.02 to $1.04 on revenue of $1.37 billion to $1.45 billion.

Gross margin rose to 86.7% from 85.8% amid the increased revenue.

Sales of Botox, which is used as a medical treatment and wrinkle-fighting cosmetic tool, rose 8.8% to $431.6 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue-increased 8.1%, or roughly 11% excluding currency fluctuations.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on ALLERGAN, INC.
01:07p KYTHERA BIOPHARMACEUTICALS : KYTH INVESTOR ALERT: The Law Offices of Vincent Won..
06/29 KYTHERA BIOPHARMACEUTICALS : NASDAQ:KYTH) Shareholder Notice: Investigation of T..
06/28 ALLERGAN : Selects Richmond Plastic Surgeon to Exclusively Offer Newly Released ..
06/26 ALLERGAN : Selects Richmond Plastic Surgeon to Exclusively Offer Newly Released ..
06/25 CANADA'S VALEANT APPROACHES TO BUY Z : Wsj
06/24 ALLERGAN : Recent FDA Approval of New Breast Implant Highlights the Ongoing Dema..
06/24 KYTHERA BIOPHARMACEUTICALS : Law Firm Kirby McInerney LLP Investigating Potentia..
06/24 KYTHERA BIOPHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairn..
06/24 KYTHERA BIOPHARMACEUTICALS : Investor Alert: Peiffer Rosca Wolf Law Firm Investi..
06/23 PARATEK PHARMACEUTICALS : Set to Join Russell 3000(R) and Russell Global Indexes
Advertisement
Income Statement Evolution
More Financials